<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185337</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0461</org_study_id>
    <secondary_id>NCI-2019-07316</secondary_id>
    <secondary_id>2019-0461</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04185337</nct_id>
  </id_info>
  <brief_title>Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes</brief_title>
  <official_title>The Role of Ultrasound-Guided Photoacoustic Imaging in Detection of Metastases in Inguinal Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies how well ultrasound-guided photoacoustic imaging works in
      telling the difference between healthy and cancerous inguinal (groin) lymph nodes and how
      well it can detect certain features of lymph nodes, including size and shape in patients with
      cancer. Ultrasound-guided photoacoustic is a non-invasive imaging method that can detect and
      display characteristics of lymph nodes based on the level of oxygen in the cells. This
      imaging method may provide more accurate tumor staging and prevent unnecessary surgical
      interventions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To estimate the mean difference in oxygen saturation (%sO2) between healthy and malignant
      inguinal lymph nodes using ultrasound-guided photoacoustic imaging (PAI) in cancer patients.

      SECONDARY OBJECTIVE:

      I. To examine the role of ultrasound-guided PAI in detecting metastases in the inguinal lymph
      nodes and ultrasound features of lymph nodes such as the size, shape of the lymph nodes.

      OUTLINE:

      Patients undergo standard of care ultrasound of the lymph nodes, then undergo
      ultrasound-guided PAI over 3-5 minutes. Patients then undergo standard of care
      ultrasound-guided fine needle aspiration (FNA) or biopsy a suspicious lymph node.

      After completion of study, patients are followed up for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 11, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between background oxygen saturation (%sO2) and nodal %sO2</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>For each suspicious lymph node, a %sO2 throughout the entire lymph node volume will be obtained. The %sO2 from the tissue immediately surrounding each lymph node will also be calculated to account for variations in background %sO2. The tumor status will be confirmed with ex vivo histopathology. Will scan normal lymph nodes in the same or contralateral inguinal region and will use as controls. Data will be analyzed once the benignities of these lymph nodes are determined.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo standard of care ultrasound of the lymph nodes, then undergo ultrasound-guided PAI over 3-5 minutes. Patients then undergo standard of care ultrasound-guided FNA or biopsy a suspicious lymph node.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fine-Needle Aspiration</intervention_name>
    <description>Undergo ultrasound-guided FNA</description>
    <arm_group_label>Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)</arm_group_label>
    <other_name>Aspirate, Fine Needle</other_name>
    <other_name>Fine Needle Aspiration</other_name>
    <other_name>fine-needle aspiration biopsy</other_name>
    <other_name>FNA</other_name>
    <other_name>FNA biopsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymph Node Biopsy</intervention_name>
    <description>Undergo ultrasound-guided lymph node biopsy</description>
    <arm_group_label>Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)</arm_group_label>
    <other_name>Biopsy of Lymph Node</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photoacoustic Imaging</intervention_name>
    <description>Undergo ultrasound-guided PAI</description>
    <arm_group_label>Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Undergo ultrasound</description>
    <arm_group_label>Diagnostic (ultrasound, ultrasound-guided PAI, FNA, biopsy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven primary malignancy

          -  Suspicious inguinal lymph nodes for metastasis on a conventional imaging modality

          -  Scheduled to undergo ultrasound-guided fine needle aspiration cytology or biopsy

        Exclusion Criteria:

          -  Melanoma patients, since the melanocytes may have a &quot;masking effect&quot;

          -  The deeper inguinal lymph nodes (3-5 cm deep) and smaller (&lt; 1 cm in short axis) in
             dimensions will be excluded from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priya R Bhosale</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Priya R. Bhosale</last_name>
    <phone>713-792-0221</phone>
    <email>priya.bhosale@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Priya R. Bhosale</last_name>
      <phone>713-792-0221</phone>
    </contact>
    <investigator>
      <last_name>Priya R. Bhosale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

